[Form 4] Abbott Laboratories Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing overview: Abbott Laboratories (ABT) Executive Vice President Louis H. Morrone reported one transaction dated 30 June 2025.

• Transaction code: F (as reported in the form).
• Shares affected: 269 common shares without par value.
• Transaction price: $134.38 per share.
• Post-transaction direct holdings: 66,609 common shares.
• Indirect holdings: 12 common shares held in the Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) as of 30 June 2025.

There were no derivative security transactions reported and no indication of additional purchases, option exercises, or sales beyond the single Code F entry. Morrone remains an insider with substantial equity exposure to Abbott Laboratories after the reported withholding.

Insights

Securities Analyst

TL;DR — Minor insider share disposition; immaterial to ABT valuation.

The Form 4 shows Executive Vice President Louis H. Morrone had 269 shares withheld/disposed at $134.38 on 30 June 2025, leaving 66,609 directly held shares plus 12 indirect shares. The volume represents a fraction of his ownership and an immaterial percentage of Abbott’s total shares outstanding. No derivative activity or multiple insiders were involved. Given the small size and lack of market-moving context, the filing is neutral for investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morrone Louis H.

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXECUTIVE VICE PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	06/30/2025		F		269	D	$134.38	66,609	D
Common shares without par value								12(1)	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of June 30, 2025.

	/s/ Louis H. Morrone by Jessica H. Paik, Attorney-in-Fact	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Abbott Laboratories (ABT) shares did Louis H. Morrone dispose of on 30 June 2025?

269 common shares according to the Form 4 filing.

What was the transaction price for the ABBOTT LABORATORIES shares?

The shares were priced at $134.38 per share.

How many ABT shares does Morrone own after the reported transaction?

He holds 66,609 shares directly and 12 shares indirectly through the Stock Retirement Trust.

Were any derivative securities involved in this Form 4 filing for ABT?

No. No derivative security transactions were reported.

What is Louis H. Morrone’s role at Abbott Laboratories?

He is an Executive Vice President, as stated in the filing.